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Abstract
Lung cancer remains the most common cause of cancer-related mortality. We applied a highly multiplexed proteomic
technology (SOMAscan) to compare protein expression signatures of non small-cell lung cancer (NSCLC) tissues with
healthy adjacent and distant tissues from surgical resections. In this first report of SOMAscan applied to tissues, we highlight
36 proteins that exhibit the largest expression differences between matched tumor and non-tumor tissues. The
concentrations of twenty proteins increased and sixteen decreased in tumor tissue, thirteen of which are novel for NSCLC.
NSCLC tissue biomarkers identified here overlap with a core set identified in a large serum-based NSCLC study with
SOMAscan. We show that large-scale comparative analysis of protein expression can be used to develop novel
histochemical probes. As expected, relative differences in protein expression are greater in tissues than in serum. The
combined results from tissue and serum present the most extensive view to date of the complex changes in NSCLC protein
expression and provide important implications for diagnosis and treatment.
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Introduction
Progression from healthy state to disease is accompanied by
changes in protein expression in affected tissues. Comparative
interrogation of the human proteome in healthy and diseased
tissues can offer insights into the biology of disease and lead to
discovery of new biomarkers for diagnostics, new targets for
therapeutic intervention, and identification of patients most likely
to benefit from targeted treatment. In particular, new diagnostics
for early detection of lung cancer are urgently needed. For the
purposes of treatment and prognosis, lung cancer is classified
pathologically as either small cell (15%) or non-small cell (85%).
Lung cancer is the leading cause of cancer deaths, largely because
84% of cases are diagnosed at an advanced stage, with a five-year
survival rate of less than 15% [1–3]. Worldwide in 2008, 1.5
million people were diagnosed and 1.3 million died – a survival
rate unchanged since 1960 [4]. However, patients diagnosed with
NSCLC at an early stage and treated surgically to remove their
tumors experience an 86% five-year survival [1,2].
We recently developed a novel affinity-based proteomic
technology for biomarker discovery that currently measures over
1,000 proteins from small sample volumes of plasma or serum (e.g.
,10 mL of plasma) with low limits of detection (median value of
300 fM), 7 logs of overall dynamic range (,30 fM – 1 mM, using
sample dilution), and 5% median coefficient of variation [5]. This
technology, called SOMAscan, is enabled by SOMAmers (Slow
Off-rate Modified Aptamers), a new class of protein binding
reagents that contain chemically modified nucleotides, which
greatly expand the physicochemical diversity of the nucleic acid
libraries. Such modifications introduce functional groups that are
often found in protein-protein interaction, antibody-antigen
interactions, and interactions between small-molecule drugs with
their protein targets, but are absent in natural nucleic acids. These
modifications are compatible with the SELEX (Systematic
Evolution of Ligands by EXponential Enrichment) process used
to create SOMAmers as well as standard DNA methods including
PCR and hybridization. Overall, the use of these modifications
expands the range of possible targets for SELEX, results in
improved binding properties, and facilitates selection of SOMA-
mers with slow dissociation rates [5].
SOMAscan is a highly multiplexed platform for quantitatively
measuring proteins in complex matrices such as plasma or serum
in which a signature of protein concentrations is transformed into
a corresponding DNA signature, which is then quantified on a
commercial DNA microarray platform [5]. Briefly, equilibrium
binding between a mixture of SOMAmers and proteins is achieved
in solution, followed by removal of unbound species by successive
bead-based immobilization steps accompanied with extensive
washing. High specificity, already an intrinsic feature of SOMA-
mers, is additionally enhanced with the inclusion of dextran sulfate
during binding and washing steps. Dextran sulfate, which like
nucleic acids is a polyanion, is effective because cognate
SOMAmer-protein complexes are more kinetically stable than
non-specific complexes. At the end of the assay, specific
SOMAmer-protein complexes remain from which SOMAmers
can be eluted under denaturing conditions, hybridized on
commercially available microarrays, and directly quantified
through a fluorophore covalently coupled to the SOMAmer. In
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SOMAmers as both folded binding entities with defined shapes
and unique nucleic acid sequences recognizable by specific
hybridization probes. The utility of this assay has been shown
previously in simultaneous measurements of large numbers of
proteins ranging from low picomolar to high micromolar
concentration in plasma and serum and clinical biomarker studies
of chronic kidney disease and lung cancer [5,6].
Results
Proteomic analysis of NSCLC surgical resections
In this report, we performed large-scale protein expression
analysis of homogenized lung tissue samples from surgical
resections obtained from eight non-small cell lung cancer
(NSCLC) patients. All NSCLC patients were smokers, ranging
in age from 47 to 75 years old and diagnosed with pathology-
confirmed NSCLC stages IA through IIIB (Table 1). We obtained
three samples from each resection: tumor tissue sample, adjacent
non-tumor tissue (within 1 cm of the tumor) and distant
uninvolved lung tissue (furthest edge of the resection from the
tumor). Care was taken to preserve the integrity of the tissue, with
all samples being frozen within 5–10 minutes of excision. Total
protein concentration was adjusted and normalized in each
homogenate for proteomic profiling followed by analysis on our
biomarker discovery array to measure the concentrations of 820
human proteins as recently described [5].
These protein concentration measurements, expressed as
relative fluorescence units (RFU), allow large-scale comparisons
of protein signatures among samples (Fig. 1). We first compared
the protein expression levels between the adjacent and distant
tissue samples for each patient (Fig. 1A). Overall, the signals
generated by most analytes were similar in adjacent and distant
tissue. In this comparison, only one analyte (fibrinogen) exhibited
more than a two-fold difference between the two control samples.
Fibrinogen concentration was higher in adjacent non-tumor tissue
than distant non-tumor tissue. Fibrinogen is the soluble precursor
of fibrin, which is converted by thrombin during coagulation.
Fibrin deposits occur within adjacent stroma of most tumors,
primarily in the extracellular matrix (ECM) where fibrin and other
ECM proteins promote and support tumor growth processes
including, cell proliferation, adhesion, invasion, migration, and
angiogenesis [7].
In contrast, comparison of tumor tissues with non-tumor tissue
(adjacent or distant) identified 11 (1.3%) proteins with greater than
four-fold differences and 53 (6.1%) proteins with greater than two-
fold differences (Figs. 1B and 1C). The remaining (93.9%) proteins
showed relatively small differences between tumor and non-tumor
tissue. Some proteins were substantially suppressed while others
were elevated in tumor tissues compared to adjacent or distant
tissues. Differential expression of proteins between adjacent and
tumor tissue, or between distal and tumor tissue, was similar
overall. Changes in between tumor and distal tissue were generally
somewhat larger compared to tumor and adjacent tissue (Fig. 1),
which demonstrates that most observed protein changes are
specific to the local tumor environment. Figure 2 shows a heat
map depiction of the results. There was a trend of protein changes
reflecting pathologic stage, which may indicate that protein
expression correlates with disease burden. Given the small sample
size, correlations with histological classification could not be
decoupled from stage.
Biomarker identification
To identify potential NSCLC tissue biomarkers, we looked for
analytes with the largest change in protein expression levels
between tumor, adjacent, and distant tissue samples. Here we
highlight thirty-six proteins with the largest mean fold-change in
protein expression between tumor and non-tumor tissue samples
(Fig. 3, Table 2). We tested the significance of these changes with
the Mann Whitney test and required a p-value of 0.05 after
correcting for multiple tests (false discovery rate cutoff of q,0.05).
Although the number of samples we used for this study was
relatively small, the study consisted of paired tumor and non-
tumor tissue samples from each individual. This provides more
power to identify changes within an individual and eliminates the
population variance associated with cross-sectional study designs.
The availability of appropriately chosen reference samples is
increasingly recognized as a crucially important component in
biomarker discovery research [8–10]. Finally, we assessed
reproducibility of this new method by analyzing triplicate samples
of tumor and non-tumor tissue resections for two subjects in
this study and found a 4.5% median CV between triplicate
Table 1. Patient demographics, resection location and tumor types for the eight NSCLC analyzed samples.
Age Sex Smoking History Location Stage Tissue Dx
47 F Smoker Left Upper Lobe pT3pN1pMx stage IIIA Poorly differentiated non-small cell CA with
focal squamous differentiation
73 F Smoker Left Lower Lobe pT2pN0pMx stage IB Poorly differentiated squamous cell
carcinoma
48 M Smoker Right Upper Lobe pT2pN1pMx stage IIIA Poorly differentiated squamous cell
carcinoma
60 F Smoker Left Upper Lobe T4 N1 M0 stage IIIB - note T4 distinction
based on clinical lung collapse; tumor was
pT2 by size criteria
Poorly differentiated squamous cell
carcinoma
51 F Smoker Right Upper Lobe pT2pN0pMx stage IB Moderately differentiated adenocarcinoma
71 F Smoker Right Upper Lobe pT2pN0pMx stage IB Well differentiated adenocarcinoma
75 F Smoker Right Lower Lobe pT1N0Mx Stage IA Well differentiated adenocarcinoma
73 M Smoker Left Upper Lobe pT1bN0Mx Stage IA Atypical carcinoid tumor (i.e.
neuroendocrine, IHC positive for
chromogranin)
doi:10.1371/journal.pone.0035157.t001
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Spearman correlation coefficients .0.99 (partially inflated by the
large RFU range measured). Triplicate measurements for the 36
proteins with largest mean-fold differences between tumor and
non-tumor tissue are plotted in Fig. 5.
High-content proteomic analysis of biological samples enabled
by our multiplexed assay allows unbiased discovery of disease-
related proteins. To date, we have conducted several blood-based
clinical biomarker studies of human diseases, including lung
cancer [6] and chronic kidney disease [5]. These studies have
identified novel potential disease biomarkers as well as biomarkers
that have been reported previously. The current study follows this
trend. About one-third (13/36) of the potential NSCLC tissue
biomarkers identified here are novel, to the best of our knowledge.
The remaining two-thirds (23/36) have been reported previously
as differentially expressed proteins or genes in NSCLC tumor
tissue (Table 2). Novelty was determined by performing literature
searches in Pubmed and on the internet using the potential
biomarkers’genenamesand proteinaliasesasidentifiedbyUniProt.
Figure 1. Relative changes in protein expression for 820 proteins from eight NSCLC resection samples. Signal differences between
adjacent and distant tissue (panel A), tumor and adjacent tissue (panel B) and tumor and distant tissue (panel C) are expressed as log2 median ratios.
The dotted line represents two-fold change (log2=1).
doi:10.1371/journal.pone.0035157.g001
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biological processes associated with important hallmarks of tumor
biology [11] as shown in Table 3: 1) angiogenesis, 2) growth and
metabolism, 3) inflammation and apoptosis, and 4) invasion and
metastasis. Admittedly, these are convenient but inexact classifi-
cations that approximate a highly complex and dynamic system in
which these molecules often play multiple and nuanced roles.
Therefore, the specific state of a given system ultimately affects
the expression and function of any particular molecule. Our
understanding of the biological underpinnings of these systems
is far from complete. With the SOMAscan platform, we are
beginning to explore the quantitative expression of large numbers
of proteins in various tissues and disease processes. These data
provide new coordinates to help map the dynamics of these
systems, which in turn will provide a more complete understand-
ing of the biology of this disease. The results from the current
study provide a new perspective on NSCLC tumor biology, with
both familiar and new elements.
Angiogenesis
Angiogenesis drives growth of new blood vessels to support
tumor growth and metabolism. The regulation of angiogenesis is a
complex biological phenomenon controlled by both positive and
negative signals [11]. Among the potential NSCLC tissue
biomarkers identified in this study (Fig. 3) were well known
positive and negative angiogenesis regulators, all of which have
been observed previously in NSCLC tumor tissue [12–16]. These
include the prototypic angiogenesis inducer VEGF and inhibitors
endostatin and thrombospondin-1 (TSP-1). VEGF is a powerful
growth factor that promotes new blood vessel growth; VEGF was
strongly up-regulated in NSCLC tumor tissue, consistent with
previous observations [12], including our study of serum samples
from NSCLC patients [6]. It is worth noting that VEGF was
originally discovered as tumor cell-secreted vascular permeability
factor (VPF) that increased the leakiness of tumor-associated blood
vessels to large molecules, such as fibrinogen, that are normally
confined to plasma [17]. This activity may have profound effects
on the composition of proteins associated with tumor tissue.
Figure 2. Heat map of protein levels in tumor tissue samples. The samples are displayed in columns and separated into distant non-tumor,
adjacent non-tumor, and tumor tissue. Within each tissue type, the samples are separated into adenocarcinomas (AC) or squamous cell carcinomas
(SCC). The numbers above each column correspond to patient codes. The proteins are displayed in rows and were ordered using hierarchical
clustering.
doi:10.1371/journal.pone.0035157.g002
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strong inhibitor of endothelial cell proliferation and angiogenesis
[13]. TSP-1 and the related TSP-2 were substantially up-regulated
in NSCLC tumor tissue. TSP-1 and TSP-2 are extracellular
matrix proteins with complex, context-dependent effects modu-
lated through a variety of interactions with cell-surface receptors,
growth factors, cytokines, matrix metalloproteinases, and other
molecules. Archetypically in model systems, TSP-1 and TSP-2
inhibit angiogenesis by inhibiting endothelial cell proliferation
through the CD47 receptor (not measured in this study) and
inducing endothelial cell apoptosis through the CD36 receptor.
There is also evidence for proangiogenic influences for TSP-1 and
TSP-2 [18]. Finally, reported TSP-1 and TSP-2 relative and
absolute expression levels in NSCLC tissue vary [16,19–21] likely
Figure 3. Box plots of SOMAmer signals in the tissue homogenates. Proteins with increased (panel A) or decreased (panel B) levels in tumor
tissue compared with adjacent or distal tissue (panel A) from eight NSCLC samples used in this study. Each individual is indicated with a different
symbol. The horizontal lines of each box correspond to the first, second, and third quartiles (25%/50%/75%) and the whiskers correspond to the
maximum and minimum values.
doi:10.1371/journal.pone.0035157.g003
Table 2. SOMAscan protein expression differences expressed as log2 ratio of the signal in tumor to non-tumor tissue samples for
proteins with the largest mean-fold change.
Protein Target Adjacent Distant NSCLC Tissue Expression Changes Reported in Literature
Activin A 1.16 0.88 Protein [39]; Gene [39–41]
Adiponectin 20.99 21.00 None
BCA-1 1.91 2.24 None
Biglycan 21.88 21.14 None
Cadherin-1 1.33 1.21 Protein [42–45]
Carbonic anhydrase III 22.22 22.13 None
Caspase-3 0.95 0.98 Protein [46,47]; Gene [41,48]
Catalase 21.03 20.93 Protein [49,50]; Gene [50,51]
CD36 20.91 21.24 Gene [52]
CXCL16, soluble 20.93 21.00 None
Endostatin 21.03 21.12 Protein [13,14,53]
ESAM 21.52 21.81 Protein [54]
Fibronectin 1.92 1.58 None
IGFBP-2 2.42 2.58 Gene [55,56]
IGFBP-5 2.45 1.77 Gene [56,57]
IGFBP-7 1.52 0.47 Protein [58,59]
IL-8 1.80 1.76 Protein [60]; Gene [52,60,61]
Insulysin 0.78 1.10 None
MAPK13 1.28 0.89 None
MMP-7 1.91 2.11 Protein [26,62]; Gene [52,63]
MMP-12 3.53 4.19 Protein[26,27]; Gene [27,41,51,64]
MRC1 21.36 21.96 None
NAGK 0.83 1.24 None
NAP-2 21.11 21.44 Gene [41]
P-Selectin 21.57 21.78 None
SLPI 21.77 20.85 Gene [51]
sRAGE 25.77 25.44 Protein [25,65]; Gene [25,41,51,65]
Thrombospondin-1 1.70 1.23 Protein [20]; Gene [40,52]
Thrombospondin -2 1.80 1.93 Protein[66]; Gene [40,52,66]
TrATPase 22.26 22.87 None
Tryptase b-2 22.68 22.24 Protein [67]
uPA 1.08 0.94 Protein [68]; Gene [52,64,68,69]
URB 2.11 1.41 None
VEGF 1.88 1.34 Protein [12,14]; Gene [15,41,51]
vWF 20.98 21.18 Gene [41,51]
YES 0.85 1.02 Gene [70,71]
doi:10.1371/journal.pone.0035157.t002
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CD36 was down-regulated in NSCLC tumor tissue, which could
indicate an adaptation of tumor cells reduce sensitivity to TSP-1
and TSP-2-mediated apoptosis.
Growth and Metabolism
Ten of the potential NSCLC biomarkers we identified are
associated with growth and metabolism functions. Half of these
biomarkers are involved in the complex hormonal regulation of
cellular growth and energy metabolism. Three insulin-like growth
factor binding proteins (IGFBPs), which modulate the activity of
insulin-like growth factors (IGFs), were up-regulated in NSCLC
tumors (IGFBP-2, -5, and -7). Several reports have qualitatively
assessed IGFBP-2, -5, and -7 in NSCLC (Table 2) and suggest
higher expression in NSCLC tissue than in normal tissue. Insulin
and IGFs act as hormones that strongly influence cellular growth,
metabolism, and survival. Cancer cells are often dependent on
these molecules for growth and proliferation [11]. IGFBP-2 has
also been associated with an anti-apoptotic effect via caspase-3
[22]. These hormones are in turn degraded by insulysin [23],
whose concentration was higher in NSCLC tumor tissue. The
hormone adiponectin controls lipid metabolism and insulin
sensitivity, and we found adiponectin down-regulated in NSCLC
tumors. The remaining five biomarkers, carbonic anhydrase III,
NAGK, TrATPase, tryptase b-2, and MAPK13, are all enzymes
with known roles in cellular metabolism (Table 3).
Inflammation and Apoptosis
Inflammation and apoptosis are hallmarks of cancer biology,
and we find a number of potential biomarkers associated with
these processes that have been associated previously with NSCLC
(Table 2). We found caspase-3 concentrations higher in NSCLC
tumor tissue. Caspase-3 has been associated with metastasis [24].
Another notable example is soluble receptor for advanced
glycation end-products sRAGE, which has been reported to be
dramatically down-regulated in NSCLC tissue [21,25]. This
finding is consistent with our measurement, in which sRAGE
had the largest observed change for proteins that are lower in
tumor than in non-malignant tissue. One hypothesis is that RAGE
plays a role in epithelial organization, and decreased levels of
RAGE in lung tumors may contribute to loss of epithelial tissue
structure, potentially leading to malignant transformation [25].
Several chemokines, such as BCA-1, CXCL16, IL-8, and NAP-2,
are altered in our study, consistent with the hypothesis that
invasion of tumors with cells from the innate and adaptive arms of
the immune system provide bioactive molecules that affect
proliferative and angiogenic signals [11].
Invasion and Metastasis
The largest group of potential biomarkers contains proteins that
function in cell-cell and cell-matrix interactions and are involved
in invasion and metastasis. Many have been previously reported to
be associated with NSCLC. Most notable are two of the matrix
metalloproteases, MMP-7 and MMP-12, which contribute to
proteolytic degradation of extracellular matrix components and
processing of substrates such as growth factors. For example, the
major substrate for MMP-12 is elastin. Such processes are well
known to play a role in creating tumor microenvironments. We
observed MMP-7 and MMP-12 up-regulated in NSCLC tissue,
which is consistent with similar study that used antibody-based
measurements [26]. The over-expression of MMP-7 and MMP-12
has been associated with poor prognosis in NSCLC [26]. MMP-12
levels have been correlated with local recurrence and metastatic
disease [26]. It is interesting to note that two of the eight subjects
studied had normal levels of MMP-12, whereas the other six had
15–50-fold elevation of MMP-12 in tumor tissue compared to
non-tumor tissue.
SOMAmers as histochemistry probes to NSCLC
biomarkers
Understanding the differences in protein expression between
tumor and non-tumor tissues can identify novel histochemistry
targets. This approach was used previously with MMP-12 and
others [27]. Such probes can enable more precise molecular
characterization of tumors and their effects on the surrounding
stroma. We have previously demonstrated that fluorophore-
labeled SOMAmers confer rapid and selective histochemical
staining in frozen tissue sections [28]. Here we examined tissue
staining by several of the SOMAmers that were identified as
biomarkers in our analysis of tissue homogenates. Frozen tissue
sections were cut from the same tumor resections used for
biomarker discovery. For example, TSP-2 staining with a
fluorophore-labeled SOMAmer in tumor tissue was striking and
localized predominantly in areas of fibrous stromal scarring
(Fig. 6A), but such staining was largely absent in normal tissue
(Fig. 6B). This is consistent with the reported role of TSP-2 in
matrix modulation [18,29]. In contrast, in normal lung tissue, the
macrophage mannose receptor (MRC1) SOMAmer staining
localized to the surface of alveolar macrophages (Fig. 6D) as
expected for this target [30]. Tumor tissue samples, which lack
alveoli, showed little MRC1 staining (Fig. 6C). Figure 6E
demonstrates MRC1 SOMAmer staining performed concurrently
with antibody-based immunofluorescence for other targets (cyto-
keratins and CD31), indicating the feasibility of multiplexing
SOMAmer and antibody reagents in histologic studies. Tissue
staining with SOMAmers was thus consistent with the homoge-
nate profiles, in which TSP-2 was elevated and MRC1 was
decreased in tumor versus healthy tissue. We confirmed the
SOMAmer staining patterns of TSP-2 and MRC1 with antibodies
Figure 4. Plot of the cumulative density function (CDF) for the
coefficient of variation (CV) between triplicate samples. The
tumor, adjacent non-tumor, and distant non-tumor tissue resections
were sampled, extracted, and analyzed with the SOMAscan proteomic
assay in triplicate for two individuals in the study. The median CV for all
6 triplicates was 4.5% (black line).
doi:10.1371/journal.pone.0035157.g004
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the direction of change in protein expression between tumor and
healthy tissue homogenates provides additional evidence that the
identified biomarkers are associated with disease. Large-scale
proteomic comparison between tissues described here is also a
powerful method for identifying novel histochemical probes.
Some general caveats related to discovery of potential NSCLC
biomarkers are worth noting. First, the fact that a protein is
associated with tumor tissue need not mean that it is specific for
tumor tissue. For example, inflammation, extracellular matrix
remodeling, hypoxia, and tissue necrosis accompanies tumor
progression but also many other non-malignant conditions such as
injury, wound healing or infection. Second, biomarkers we
identified could reflect a difference in the ratio of cell types that
constitute a tumor sample compared to that of the normal lung
tissue. For example, if tumor tissue consists of cancer cell
overgrowth, some of the biomarkers are expected to be specific
for that cell type (in this case, epithelial cells), transformed or not.
Similarly, if a tumor tissue sample is either more or less
vascularized than the surrounding normal tissue, a change in the
Figure 5. Plots of triplicate samples for the 36 analytes with the largest mean fold-change in protein expression between tumor
and non-tumor tissue samples (Table 2). The tumor, adjacent non-tumor, and distant non-tumor tissue resections were sampled, extracted, and
analyzed with the SOMAscan proteomics assay in triplicate for two individuals (patients 56 and 61) in the study. The samples are colored by individual
and the tumor samples are highlighted as triangles. The y-axis is on a log scale.
doi:10.1371/journal.pone.0035157.g005
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Indeed, we observed significantly lower concentrations of ESAM,
a protein specific to endothelial cells, compared to matched, non-
tumor tissue. We confirmed this histochemically, as shown in
Figure 8, where we measured 35-fold more ESAM-positive
endothelial cells in distant non-tumor tissue compared to tumor
tissue. Finally, SOMAmers, like all affinity reagents, bind and
recognize specific epitopes of target proteins generally in a
conformation-dependent manner, and any particular measure-
ment reflects the availability of that epitope.
Comparison of NSCLC tissue and serum biomarkers
We have recently completed a NSCLC study [6] in which we
analyzed 1,326 serum samples from four independent clinical
study centers using the same proteomic platform and a protein
menu nearly identical to the that used for tissue (813/820 proteins
). The study included patients diagnosed with pathologic or clinical
stage I–III NSCLC and a control population with a history of
long-term tobacco use, including active smokers and ex-smokers
with at least 10 pack-years of cigarette smoking. Taking extensive
precautions to account for pre-analytic variables, we identified 44
candidate biomarkers, and developed a 12-protein panel that
distinguished NSCLC from controls with 91% sensitivity and 84%
specificity in a training set, and 89% sensitivity and 83% specificity
in a blinded, independent verification set. The availability of this
database allows us to compare changes in protein expression in
tissue and serum from NSCLC patients.
While the methodology used to analyze the protein profiles in
samples from these two NSCLC studies is the same, some
significant differences are worth noting. First, serum pre-analytic
variability was observed between study centers, perhaps masking
some cancer biomarkers [6]. Second, in the NSCLC tissue study
reported here, each tumor sample has its own control tissue
(adjacent and distant non-tumor), whereas the larger NSCLC
serum study by necessity is composed of case and control samples
from different individuals. Nevertheless, differential expression of
proteins in sera of NSCLC patients relative to cancer-free controls
compared with that of NSCLC tissue samples yields useful
insights (Fig. 9, Table 4). The most striking observation is that
relative changes in protein expression are greater in tissues than in
serum. This result could be expected since tumor tissue is the
source of the changes in protein expression that is then, even if
fully released into circulation, diluted many-fold into total volume
of blood. This trend is evident in the elongated distribution ofdata
points along the x-axis in Figure 9 in which axes are drawn on the
same scale to illustrate this point. Eleven of the analytes shown in
Figure 3 as altered in tumor tissue were also differentially
expressed in sera from NSCLC patients vs. controls (filled red
circles in Fig. 9). It is worth noting that our published NSCLC
serum study [6] did not measure MMP-12, which this study
identified as a top tissue biomarker. In subsequent NSCLC serum
Table 3. Categorization of NSCLC tissue biomarkers into biological major processes.
Angiogenesis Growth and Metabolism Inflammation & Apoptosis Invasion, Metastasis (ECM)
VEGF Adiponectin* Activin A Biglycan*
Endostatin Carbonic anhydrase III* BCA-1* Cadherin-1
Thrombospondin-1 IGFBP-2 Catalase CD36
Thrombospondin-2 IGFBP-5 CXCL16, soluble* ESAM
IGFBP-7 IL-8 Fibronectin*
Insulysin* MRC1* MMP-7
NAGK* NAP-2 MMP-12
TrATPase* sRAGE P-Selectin*
Tryptase b-2 SLPI URB*
MAPK13* uPA vWF
Caspase-3 Thrombospondin-1
Thrombospondin-2
YES
*Novel NSCLC Biomarker.
doi:10.1371/journal.pone.0035157.t003
Figure 6. SOMAmer histochemistry on frozen tissue sections
for selected biomarkers detected in this study. (A) Thrombos-
pondin-2 SOMAmer (red) staining the fibrocollagenous matrix sur-
rounding a tumor nest. (B) Corresponding normal lung specimen
stained with Thrombospondin-2 SOMAmer (red). (C) Macrophage
mannose receptor SOMAmer (red) staining scattered macrophages in
a lung adenocarcinoma. (D) Macrophage Mannose Receptor SOMAmer
(red) staining numerous alveolar macrophages in a section of normal
lung parenchyma. (E) Multicolor image highlighting the cytomorpho-
logic distribution of macrophage mannose receptor SOMAmer staining:
Green=Cytokeratin (AE1/AE3 antibody), Red=CD31 (EP3095 Antibody),
and Orange=SOMAmer. All nuclei in this figure are counterstained with
DAPI.
doi:10.1371/journal.pone.0035157.g006
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serum biomarker with a KS-distance of 0.42 (Table 2). This
suggests that elevated serum MMP-12 directly reflects NSCLC
tumor biology. Most of the other biomarkers common to tissue
and serum also change in the same direction, but a few do not.
Local concentrations of proteins in a tissue homogenate clearly
need not correlate with circulating levels of the proteins and
inverse correlations may provide clues regarding the redistribu-
tion of certain biomarkers in diseased versus normal tissues.
Discussion
The discovery of novel biomarkers with demonstrable diagnos-
tic or clinical utility has been a considerable challenge in recent
years [8]. The reasons for this include: the omnipresence of pre-
analytical and analytical artifacts, unavailability of suitable
healthy-state controls, issues related to study designs, and the
difficulty of detecting small changes in protein levels at very low
concentrations. This challenge is especially pronounced with
cancer biomarkers where the objective is often to find biomarkers
of a tiny malignancy in the blood of a relatively large human body
at an early stage.
The recently completed National Lung Screening Trial
(NLST) reported a significant mortality benefit of screening for
NSCLC with low dose CT and detecting early stage disease in a
high risk population [31]. However, the high false positive rate
results in a low (4%) positive predictive value (PPV) and potential
harm from over diagnosis and unnecessary treatment. Comple-
mentary biomarkers that would either identify individuals who
would most benefit from CT screening or improve the PPV value
of imaging are in the research phase but not are yet in clinical
use. Both miRNA and proteomic signatures in tissue and plasma
have been reported [32,33]. Advances in understanding the
molecular origins of NSCLC are beginning to guide the
development of targeted therapies [34]. As reported by Sequist,
approximately half of NSCLC tumors have known driver
mutations, 22% of which are candidates for molecular targeted
therapy [35].
One way to improve the chances of discovering true cancer
biomarkers is to measure protein concentrations in both the source
of the disease, such as tumor tissue, as well as from the circulation.
Such combined results can support the validity of potential
biomarkers and separate them from experimental artifacts. In this
report, we have demonstrated that this is possible with our highly
multiplexed and sensitive proteomic assay. We have shown that
tissues, like plasma or serum, are also amenable to SOMAscan,
and the resulting comparative analysis of protein expression in
NSCLC tumor tissues with surrounding healthy lung tissues offers
Figure 7. Thrombospondin-2 (TSP-2) histochemical identifica-
tion in tissue samples. TSP-2 is identified in serial frozen sections of a
single lung carcinoma specimen by (A) a home-made rabbit polyclonal
TSP-2 polyclonal antibody, (B) the pre-immune serum from rabbits used
to make the home-made polyclonal antibody, (C) a commercial (Novus)
rabbit polyclonal TSP-2 antibody, and (D) the TSP-2 SOMAmer. The TSP-
2 SOMAmer was used to stain frozen sections of normal and malignant
lung tissue, with standard Avidin-Biotin-Peroxidase color development,
to demonstrate different morphologic distributions: (E) Strong staining
of the fibrotic stroma surrounding tumor nests, with minimal cytosolic
staining of carcinoma cells, (F) Strong staining of the fibrotic stroma
surrounding tumor nests in a mucinous adenocarcinoma, with no
significant staining of the carcinoma cells, (G) normal lung tissue,
showing strong cytosolic staining of bronchial epithelium and scattered
alveolar macrophages, and (H) strong cytosolic staining of an
adenocarcinoma, with no significant staining of the non-fibrotic,
predominantly inflammatory stroma.
doi:10.1371/journal.pone.0035157.g007
Figure 8. ESAM histochemical staining in tissue samples. ESAM
staining is shown in lung tumor (A,C) and normal lung (B,D) distant
from the tumor. Endothelial cells are visibly more abundant in the
normal lung section, consistent with the high vascularity of normal
lung. Raw images are shown in A and C, with ESAM-positive cells
identified by the CellProfiler algorithm marked with a ‘‘1’’ in images B
and D.
doi:10.1371/journal.pone.0035157.g008
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biomarkers identified from serum samples. In our case, one third
of the thirty-six tissue biomarkers reported here (BCA-1, cadherin-
1, catalase, endostatin, IGFBP-2, MRC1, MMP-7, MAPK-13,
NAGK, VEGF and YES) have been previously identified in serum
[6]. Taken together, these data contribute to further understand-
ing of the complexity of changes accompanying NSCLC and
provide us with additional potential biomarkers for the early
detection of this deadly disease.
Materials and Methods
This work was performed on deidentified samples that would
have been disposed of if not used for research. This research thus
qualified as a minimal risk to patients and their privacy, and
approval for the use of these specimens with a waiver of consent
was granted by the University of Washington’s Institutional
Review Board.
Homogenate Preparation
All tissue samples for proteomic analysis were obtained by
freezing the tissue within 5–10 minutes of excision during surgery
and after placing the tissues in OCT medium (10.24% polyvinyl
alcohol, 4.26% polyethylene glycol, and 85.5% non-reactive
ingredients). Three samples were obtained from each resection:
tumor tissue sample, adjacent healthy tissue (within 1 cm of the
tumor) and distant uninvolved lung tissue. While keeping the
samples constantly frozen, five 10-mm thick sections were cut,
trimmed of excess OCT from around the tissue, and placed into
frozen 1.5 mL microfuge tubes. Following the addition of 200 ml
homogenization buffer (40 mM HEPES, 125 mM NaCl, 5 mM
KCl at pH 7.5 plus HALT protease inhibitor cocktail (Pierce)), the
samples were homogenized in the microfuge tubes on ice with
rotary pestle for 30 seconds, until no tissue fragments were visible.
The samples were then spun in a centrifuge at 21,0006g for
10 minutes and filtered through a 0.2 mm multi-well plate filter
into a sterile multi-well plate. Five ml aliquots were taken for
micro-BCA protein assay (Pierce) and the rest of the sample was
stored frozen and sealed in 96 well plates at 270uC.
Proteomic Profiling
Sample total protein was adjusted to16 mg/mL in SB17T buffer
(40 mM HEPES, 125 mM NaCl, 5 mM KCl, 5 mM MgCl2,
1 mM EDTA, 0.05% Tween-20 at pH 7.5) for proteomic
profiling. Samples prepared in this manner were analyzed on
the SomaLogic biomarker discovery assay using Agilent slide read-
out that measures 820 human proteins as described previously [5].
The proteins against which the SOMAmers included in this assay
were selected are given in Table S1. Briefly, this assay uses
SOMAmers to transform protein concentration into a corre-
sponding DNA concentration through a series of steps involving
affinity binding and capture of biotin onto streptavidin beads. The
final DNA concentration is measured as relative fluorescence units
(RFU) from the fluorescent SOMAmer hybridized to a comple-
mentary probe on an Agilent array.
Since each of the eight tumors in the study varies in stage and
histology, we did not assume that the RFU measurements from the
tissue resections were normally distributed. Therefore, we tested
the significance of differential expression between the eight tumor
tissues and the sixteen healthy surrounding tissues using a non-
parametric test, specifically the Mann-Whitney rank sum test. We
chose to combine the two healthy tissue groups because this study
contains a small number of total samples.
A separate two-tailed Mann-Whitney test was performed for
each of the 820 human proteins measured by the SOMAscan
platform, so we corrected for multiple comparisons by applying a
false discovery rate (FDR) correction [36] and enforced a q-value
threshold of 0.05 for all analytes.
Due to the low number of samples and the non-parametric
nature of the Mann-Whitney test, we identified many significant
analytes that were only differentially expressed by a very small
magnitude. Therefore, we sorted the set of significantly differen-
tially expressed analytes by their log ratios between the tumor
samples and the healthy samples. For this paper, we chose to
highlight the 36 analytes with the highest log ratio within the set of
significantly differentially expressed analytes.
SOMAmer staining method
5 mm frozen tissue sections were immediately placed onto a
charged slide (Superfrost Plus), and the slide was then immersed in
a fixative solution of 100% ethanol (P-Selectin & ESAM) or
acetone (all other SOMAmers) for at least 30 minutes. OCT
medium was removed from slides by a 2-minute rinse in deionized
water, followed by a 2 to 5 minutes rinse in selection buffer SB-T
(40 mM Na-HEPES, pH 7.5, 52 mM NaCl, 5 mM KCl, 5 mM
MgCl2, 0.05% Tween-20). 200 nM SOMAmer solutions made up
in SB-T supplemented with 1 mM dextran sulfate (DS) were
applied for one hour to rinsed sections and then washed for
2 minutes with SB-T at 1–5uC.
Antibody staining method
5 mm frozen tissue sections were immediately placed onto a
charged slide (Superfrost Plus), and the slides were then immersed
in a 1–5uC 100% acetone fixative solution for at least 30 minutes.
The slides were removed from the chilled acetone bath and
immediately placed into 1–5uC, 1% paraformaldehyde/PBS
pH 7.4 fixative solution for 8 minutes. After fixation the
remaining OCT embedding medium was removed from slides
by two 30-second rinses in tap water followed by a 5-minute rinse
in selection buffer SB-T, pH 7.4. The tissue sections were then
blocked for 30 minutes with 10% goat serum in SB-T, pH 7.4/
50 mM glycine. Rabbit and mouse primary antibodies were
diluted into SB-T 7.4 buffer and applied to the pre-blocked slides
for at least one hour. Primary antibodies were washed from the
slides for 5 minutes with SB-T, pH 7.4 and then incubated with
either Dy549-goat anti-rabbit or Dy549-goat anti-mouse fluores-
cent secondary antibodies in SB-T, pH 7.4/300 nM DAPI for
30 minutes. The working concentration of the secondary
antibody was 3 mg/ml. The slides were finally rinsed for
5 minutes in SB-T, pH 7.4 at room temperature and cover
slipped with Fluoromount-G supplemented with 15 mM n-propyl
gallate antifade reagent. Details regarding the antibodies used are
given in Table 5.
Figure 9. Changes in protein expression in NSCLC tissue compared to serum. The top two panels show the log2 ratio (LR) derived from
serum samples versus log ratios derived from adjacent tissue and distant tissue, respectively. The bottom four panels feature zoomed portions of
plots above, indicated by the color of the plot (green for decreased and red for increased expression compared to non-tumor tissue). Analytes shown
in Figure 2 have been labeled and analytes mentioned in the publication on the serum samples are shown in filled red symbols red.
doi:10.1371/journal.pone.0035157.g009
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Fluorescence images were acquired with a Nikon 80i upright
microscope equipped with Digital Sight DS-Ri1 color camera,
mercury lamp, and optical filters appropriate for 49,6-diamidino-2-
phenylindole, dihydrochloride (DAPI) and Cy3 imaging. Data
were collected and analyzed with Nikon NIS Elements AR 3.2
software.
Nikon A1R confocal microscope method
Fluorescence images were acquired with a Nikon A1R
ECLIPSE Ti-E inverted microscope equipped with a 32-channel
PMT spectral detector unit (SDU). The Nikon SDU was used to
subtract the signal arising from autofluorescence. The confocal
imaging data was processed offline using the ROI spectral
unmixing feature provided in the Nikon NIS Elements AR 3.2
software.
Image processing method
ESAM expression was quantified and scored in single cells with
CellProfiler and CellProfiler Analyst, respectively. The version
number of CellProfiler software used for this analysis was r10997
and can be downloaded at www.cellprofiler.org [37]. Image
analysis was performed using 106images acquired on a Nikon 80i
DS-Ri1 color camera at full frame 407663116 pixel dimensions.
CellProfiler quantified the number of ESAM+ cells, defined as
cells with DAPI+ nuclei and ESAM+ immunofluorescence, after a
flat illumination field correction. The binary classification
measurement rule was generated with a gentle boosting based
supervised machine learning classifier module in CellProfiler
Analysis r1123011246 [38].
Table 4. List of potential NSCLC biomarkers identified from
serum and tissue samples.
# Protein Name NSCLC Serum NSCLC Tissue
1 Activin A Up
2 Adiponectin Down
3 AMPM2 Up
4 BCA-1 Up Up
5 Biglycan Down
6 BMP-1 Down
7 C1s Up
8C 9 U p
9 Cadherin-1 Up Up
10 Calpain I Up
11 Carbonic anhydrase III Down
12 Caspase-3 Up
13 Catalase Up Down
14 CD30 Ligand Up
15 CD36 Down
16 CDK5/p35 Up
17 CK-MB Down
18 Contactin-5 Down
19 CXCL16, soluble Down
20 Endostatin Up Down
21 ERBB1 Down
22 ESAM Down
23 FGF-17 Up
24 Fibronectin Up
25 FYN Up
26 HSP 90a Up
27 HSP 90b Up
28 IGFBP-2 Up Up
29 IGFBP-5 Up
30 IGFBP-7 Up
31 IL-15 Ra Up
32 IL-17B UP
33 IL-8 Up
34 IMB1 Up
35 Insulysin Up
36 Kallikrein 7 Down
37 KPCI Up
38 LDH-H 1 Up
39 LGMN Up
40 LRIG3 Down
41 MAPK13 Up Up
42 MEK1 Up
43 Midkine Up
44 MIP-5 Up
45 MMP-12 Up Up
46 MMP-7 Up Up
47 MRC1 Up Down
48 NACA Up
Table 4. Cont.
# Protein Name NSCLC Serum NSCLC Tissue
49 NAGK Up Up
50 NAP-2 Down
51 PARC Up
52 P-Selectin Down
53 PTN Up
54 Renin Up
55 RGM-C Down
56 SCF sR Down
57 SLPI Down
58 sL-Selectin Down
59 sRAGE Down
60 Thrombospondin-1 Up
61 Thrombospondin-2 Up
62 TrATPase Down
63 Tryptase b-2 Down
64 Ubiquitin+1U p
65 uPA Up
66 URB Up
67 VEGF Up Up
68 vWF Down
69 YES Up Up
Proteins identified in both studies are shown in boldface font.
doi:10.1371/journal.pone.0035157.t004
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Table S1 SomaLogic Selection Targets. The proteins
against which each of the SOMAmers used in the SOMAscan
assay were selected is listed.
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